Human ARIH1 (aa 110-255) Control Fragment Recombinant Protein | Invitrogen RP-102072 product information

This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.

product summary

company name :

Invitrogen

other brands :

NeoMarkers, Lab Vision, Endogen, Pierce, BioSource International, Zymed Laboratories, Caltag, Molecular Probes, Research Genetics, Life Technologies, Applied Biosystems, GIBCO BRL, ABgene, Dynal, Affinity BioReagents, Nunc, Invitrogen, NatuTec, Oxoid, Richard-Allan Scientific, Arcturus, Perseptive Biosystems, Proxeon, eBioscience

product type :

protein

product name :

Human ARIH1 (aa 110-255) Control Fragment Recombinant Protein

catalog :

RP-102072

quantity :

100 uL

price :

US 259.00

product information

Product Type :

Protein

Product Name :

Human ARIH1 (aa 110-255) Control Fragment Recombinant Protein

Catalog # :

RP-102072

Quantity :

100 uL

Price :

US 259.00

Clonality :

Recombinant

Purity :

purified

Reactivity :

Human

Applications :

Blocking Assay: Assay-dependent, Control: Assay-dependent

Species :

Human

Storage :

-20 C, Avoid Freeze/Thaw Cycles

Description :

E3 ubiquitin-protein ligase, which catalyzes ubiquitination of target proteins together with ubiquitin-conjugating enzyme E2 UBE2L3 (PubMed:15236971, PubMed:21532592, PubMed:24076655, PubMed:27565346, PubMed:23707686). Acts as an atypical E3 ubiquitin-protein ligase by working together with cullin-RING ubiquitin ligase (CRL) complexes and initiating ubiquitination of CRL substrates: associates with CRL complexes and specifically mediates addition of the first ubiquitin on CRLs targets (PubMed:27565346). The initial ubiquitin is then elongated by CDC34/UBE2R1 and UBE2R2 (PubMed:27565346). E3 ubiquitin-protein ligase activity is activated upon binding to neddylated cullin-RING ubiquitin ligase complexes (PubMed:24076655, PubMed:27565346). Plays a role in protein translation in response to DNA damage by mediating ubiquitination of EIF4E2, the consequences of EIF4E2 ubiquitination are however unclear (PubMed:25624349). According to a report, EIF4E2 ubiquitination leads to promote EIF4E2 cap-binding and protein translation arrest (PubMed:25624349). According to another report EIF4E2 ubiquitination leads to its subsequent degradation (PubMed:14623119). Acts as the ligase involved in ISGylation of EIF4E2 (PubMed:17289916). In vitro, controls the degradation of the LINC (LInker of Nucleoskeleton and Cytoskeleton) complex member SUN2 and may therefore have a role in the formation and localization of the LINC complex, and as a consequence, nuclear subcellular localization and nuclear morphology (PubMed:29689197). [UniProt]

Format :

Liquid

Applications w/Dilutions :

Blocking Assay: Assay-dependent, Control: Assay-dependent

Aliases :

ARI; ARI-1; ariadne homolog, ubiquitin-conjugating enzyme E2 binding protein, 1; ariadne RBR E3 ubiquitin protein ligase 1; ariadne, Drosophila, homolog of; ARIH1; DKFZp686O13120; E3 ubiquitin-protein ligase ARIH1; FLJ20329; FLJ93118; H7-AP2; HARI; HHARI; HUSSY-27; Monocyte protein 6; MOP6; MOP-6; Protein ariadne-1 homolog; ubcH7-binding protein; UBCH7BP; ubcM4-interacting protein; Ubiquitin-conjugating enzyme E2-binding protein 1